ArticleProceedings of the National Academy of Sciences of the United States of America2018
Genotype-targeted local therapy of glioma.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- SDS-CRISPR for Single-Nucleotide Variant Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate.BMC cancer · 2025Article
- An Analysis of 20 Cases of Parasagittal and Falcine Meningioma: Our Institutional Experience.Journal of pharmacy & bioallied sciences · 2024Article
- Translational Research Platform for Malignant Central Nervous System Tumors.Neurologia medico-chirurgica · 2024Article
- Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma.Blood · 2024Article
- Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors.Molecular cancer therapeutics · 2024Article
- Development of Zika Virus E Variants for Pseudotyping Retroviral Vectors Targeting Glioblastoma Cells.International journal of molecular sciences · 2023Article
- Isolation of Cells from Glioblastoma Multiforme Grade 4 Tumors for Infection with Zika Virus prME and ME Pseudotyped HIV-1.International journal of molecular sciences · 2023Article
- Graphene Oxide Nanoscale Platform Enhances the Anti-Cancer Properties of Bortezomib in Glioblastoma Models.Advanced healthcare materials · 2023Article
- Interfering withAnnals of translational medicine · 2022Article
- Review
- Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.Cancer cell international · 2022Review
- Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.BMC cancer · 2022Article
- Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes.Frontiers in immunology · 2022Article
- Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies.Cancers · 2021Article
- Article
- Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.Scientific reports · 2021Article
- Local Targeting of NADCancer research · 2020Article
- Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications.Scientific reports · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
33 authors at 7 institutions in 2 countries.
Ganesh M ShankarDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Ameya R KirtaneDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Julie J MillerStephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114.
Hormoz MazdiyasniDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Jaimie RognerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Tammy TaiDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Erik A WilliamsDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Fumi HiguchiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Tareq A JuratliDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Kensuke TateishiDepartment of Neurosurgery, Yokohama City University, Yokohama, Kanagawa Prefecture, Japan 236-0027.
Mara V A KoernerDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Shilpa S TummalaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Alexandria L FinkDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Tristan PensonDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Stephen P SchmidtCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.
Gregory R WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.
Aymen BaigDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Joshua M FrancisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston MA 02215.
Mikael L RinneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston MA 02215.
Julie M BattenDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Tracy T BatchelorStephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114.
Priscilla K BrastianosStephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114.
William T CurryDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Fred G BarkerDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Justin T JordanStephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Andrew S ChiLaura and Isaac Perlmutter Cancer Center, New York University School of Medicine and New York University Langone Health, New York, NY 10016.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston MA 02215.
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; rlanger@mit.edu ctraverso@bwh.harvard.edu cahill@mgh.harvard.edu.ORCID 0000-0003-4255-0492
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Giovanni TraversoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; rlanger@mit.edu ctraverso@bwh.harvard.edu cahill@mgh.harvard.edu.
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; rlanger@mit.edu ctraverso@bwh.harvard.edu cahill@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USBroad Institute · USBrigham and Women's Hospital · USNYU Langone Health · USYokohama City University · JP
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MCONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1MControlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9MTargeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomasR01CA227821 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CAHILL, DANIEL P., WAKIMOTO, HIROAKI · 2018 to 2022
$2.4MNCI NIH HHS K12 CA090354NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA227821NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244
Abstract
Aggressive neurosurgical resection to achieve sustained local control is essential for prolonging survival in patients with lower-grade glioma. However, progression in many of these patients is characterized by local regrowth. Most lower-grade gliomas harbor isocitrate dehydrogenase 1 (
Indexed as
Brain NeoplasmsGenotypeGliomaMutationAnimalsCyanidesDrug Delivery SystemsFemaleGuanidinesHumansIsocitrate DehydrogenaseMaleMiceMice, SCIDMolecular Targeted TherapyNeoplasm ProteinsCyanidesGuanidinesIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseN-(6-chlorophenoxyhexyl)-N''-cyano-N''-4-pyridylguanidineNeoplasm Proteinsgliomaintraoperative diagnosticslocal therapymetabolic therapeutics
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.